N-羟基-5-苯基-N-(苯基甲基)戊酰胺 | 158999-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-羟基-5-苯基-N-(苯基甲基)戊酰胺
• 英文名称: N-benzyl-N-hydroxy-5-phenylpentanamide
• CAS: 158999-12-3
• 化学式: C₁₈H₂₁NO₂
• 分子量: 283.4
• InChiKey: MXZUASJHVOWCLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Use of Na*/K*-ATPase inhibitors and antagonists thereof
  申请人：Khodadoust Mehran

  公开号：US20060135443A1

  公开（公告）日：2006-06-22

  The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating hypoxia-related pathological conditions, such as Alzheimer's Disease, and those involving excessive angiogenesis, especially those non-cancer pathological conditions. The invention provides the use of Na + /K + -ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents for treating such conditions. The invention also relates to the use of cardiac glycoside inhibitors/antagonists as reagents, pharmaceutical formulations, or in kits and methods for treating conditions arising from excessive amount of cardiac glycosides, including all symptoms of digitalis poisoning, depression, hypertension, etc. The pharmaceutical formulation of the invention may be delivered to a patient either systemically or locally, or both. The pharmaceutical formulations of the invention may be delivered either in one dose, or continuously over a sustained period of time using, for example, sustained drug delivery devices.

  本发明的试剂、药物制剂、试剂盒和方法为治疗缺氧相关病症（如阿尔茨海默氏症）和涉及过度血管生成的病症（尤其是非癌症病症）提供了一种新方法。本发明提供了使用 Na + /K + -ATP酶抑制剂，如强心苷（如欧阿巴因和丙种球蛋白等），单独使用或与其他标准治疗剂联合使用来治疗这些病症。本发明还涉及强心苷抑制剂/拮抗剂作为试剂、药物制剂或在试剂盒和方法中的使用，用于治疗强心苷过量引起的病症，包括洋地黄中毒、抑郁症、高血压等所有症状。本发明的药物制剂可以全身或局部给药，或两者兼用。本发明的药物制剂可以一次给药，也可以使用持续给药装置等持续一段时间连续给药。
• EP1047437A4
  申请人：——

  公开号：EP1047437A4

  公开（公告）日：2004-03-03
• SEA CUCUMBER CAROTENOID LIPID FRACTION PRODUCTS AND METHODS OF USE
  申请人：Collin, Peter Donald

  公开号：EP1047437A1

  公开（公告）日：2000-11-02
• USE OF NA+/ K+-ATPASE INHIBITORS AND ANTAGONISTS THEREOF
  申请人：BTG International Limited

  公开号：EP1812010A2

  公开（公告）日：2007-08-01
• ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION
  申请人：The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center

  公开号：EP2078079B1

  公开（公告）日：2011-05-04